Source: Annual Congress 2009 - New aspects of inhalation therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Syed, S. Balamurgan, P. A. Mahesh, C. J. Po, A. Jakkanwar, N. Sharma, S. Chachad, S. Purandare, A. Sule, A. Lulla (Mumbai, Chennai, Mysore, India). Clinical equivalence of two HFA formulations of salmeterol xinafoate in asthmatic patients using 12 hour serial spirometry. Eur Respir J 2009; 34: Suppl. 53, 2049

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 100s Year: 2007 Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007 Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Efficacy of formoterol 12μg dry powder capsules in 6,155 asthmatic patients poorly controlled with salmeterol or on-demand salbutamol (EFORA study) Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 14s Year: 2005 Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Impulse oscillometry in evaluation therapy with combination fluticasone propionate and salmeterol in asthma patients Source: Annual Congress 2007 - New insight into the pathophysiology of asthma Year: 2007 A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010